Get the Stockscreener App
32.96
0.46%
0.15
After Hours:
32.96
Mbx Biosciences Inc stock is traded at $32.96, with a volume of 317.86K.
It is up +0.46% in the last 24 hours and up +17.71% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
See More
Previous Close:
$32.81
Open:
$32.81
24h Volume:
317.86K
Relative Volume:
0.52
Market Cap:
$1.57B
Revenue:
-
Net Income/Loss:
$-86.97M
P/E Ratio:
-13.63
EPS:
-2.4189
Net Cash Flow:
$-81.88M
1W Performance:
+4.11%
1M Performance:
+17.71%
6M Performance:
+136.27%
1Y Performance:
+346.61%
1-Day Range:
$31.82
$33.50
1-Week Range:
$30.76
$33.80
52-Week Range:
$7.09
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
32.96 | 1.56B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
Stifel reiterates Buy on MBX Biosciences stock, keeps $50 target - Investing.com
Is MBX Biosciences Inc stock influenced by commodity pricesWeekly Earnings Recap & Daily Growth Stock Tips - baoquankhu1.vn
Goldman Sachs initiates coverage of MBX Biosciences (MBX) with sell recommendation - MSN
MBX Biosciences (NASDAQ:MBX) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
MBX Biosciences, Inc. focuses on science-led innovation to transform endocrine and metabolic disease treatment - Traders Union
MBX Biosciences (NASDAQ:MBX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Institution Moves: Is MBX Biosciences Inc part of any ETF2026 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative? - Yahoo Finance
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
MBX Biosciences (MBX) Is Up 16.6% After Analyst Initiation And Leadership Award News Has The Bull Case Changed? - Sahm
MBX Biosciences Approves Equity-Based Inducement Grant for New Employee Under Nasdaq Rule - geneonline.com
MBX Biosciences Reports Inducement Grant - National Today
Lifesci Capital Weighs in on MBX Biosciences Q1 Earnings - MarketBeat
MBX Biosciences (NASDAQ:MBX) Upgraded at Lifesci Capital - MarketBeat
MBX Biosciences (NASDAQ:MBX) Shares Up 8.5%What's Next? - MarketBeat
MBX Biosciences, Inc. (NASDAQ:MBX) Sees Large Increase in Short Interest - MarketBeat
MBX PE Ratio & Valuation, Is MBX Overvalued - Intellectia AI
221,672 Shares in MBX Biosciences, Inc. $MBX Acquired by Goelzer Investment Management Inc. - MarketBeat
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know - Yahoo Finance
Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - MSN
MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MBX (NASDAQ: MBX) affiliate files sale notice for 1,061 vested shares - Stock Titan
MBX Biosciences (MBX) Is Down 6.5% After Wider Losses And New Shelf Filings Has The Bull Case Changed? - simplywall.st
Hudson Bay Capital Management LP Purchases New Stake in MBX Biosciences, Inc. $MBX - MarketBeat
Aug Intraday: Can MBX Biosciences Inc keep up with sector leaders2026 Risk Factors & AI Powered Trade Plan Recommendations - baoquankhu1.vn
MBX Biosciences Advances Avail Phase 2 Trial in Hypoparathyroidism: What Investors Should Watch - TipRanks
Top MBX Biosciences (MBX) Competitors 2026 - MarketBeat
New weekly therapy moves toward Phase 3 for hypoparathyroidism - Hypoparathyroidism News
MBX Biosciences (MBX) CFO John Smither files initial Form 3 - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
MBX Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MBX Biosciences Chief Makes Bold Insider Move With Major Stock Buy - TipRanks
Company (NASDAQ: MBX) Form 144 — 10,000-share sale notice via Fidelity - Stock Titan
MBX Biosciences (NASDAQ:MBX) Shares Gap Up After Insider Buying Activity - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After Recent Share Price Pullback - simplywall.st
Hawryluk P. Kent buys MBX Biosciences shares worth $525,662 By Investing.com - Investing.com India
Hawryluk P. Kent buys MBX Biosciences shares worth $525,662 - Investing.com
MBX Biosciences (NASDAQ:MBX) CEO Buys $525,585.00 in Stock - MarketBeat
MBX Biosciences (MBX) CEO adds 18,500 shares via trust purchase - Stock Titan
MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus - Yahoo Finance
Baker BROS. Advisors LP Takes $4.86 Million Position in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences completes FDA meeting for Phase 3 trial design - Investing.com Nigeria
Ghisallo Capital Management LLC Takes $669,000 Position in MBX Biosciences, Inc. $MBX - MarketBeat
Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - MSN
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and REPRO-MED Systems (KRMD) - The Globe and Mail
MBX Biosciences Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Citizens reiterates Market Outperform on MBX Biosciences stock - Investing.com Nigeria
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):